Network Version
T863 Data Sheet
| Product Name: | T863 |
 |
|---|---|---|
| CAS No.: | 701232-20-4 | |
| Cat. No.: | HY-32219 | |
| MWt: | 394.47 | |
| Formula: | C22H26N4O3 | |
| Purity : | >98% | |
| Solubility: | DMSO : ≥ 50 mg/mL | |
| Mechanisms: | Target: Metabolic Disease | |
| Biological Activity: | ||
| T863 is an orally active, selective and potent DGAT1 (acyl-CoA:diacylglycerol acyltransferase 1) inhibitor with an IC50 of 15 nM. T863 has no inhibitory activity against human MGAT3, human DGAT2, or human MGAT2. T863 interacts with the acyl-CoA binding site of DGAT1, and inhibits triacylglycerol synthesis in cells[1][2]. IC50 & Target:IC50: 15 nM (DGAT1)[2] In Vitro:T863 (for 3 days) enhanceS insulin-stimulated glucose uptake, suggesting a possible role for adipocytes to improve insulin sensitivity upon DGAT1 inhibition in differentiated 3T3-L1 adipocytes[1]. In Vivo:T863 (30 mg/kg; oral administration) causes weight loss, reduction in serum and liver triglycerides, and improved insulin sensitivity[1]. | ||
1 Deer Park Dr, Suite F, Monmouth Junction, NJ 08852, USA
Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] Web:www.medchemexpress.com